- Investor's Business Daily•2 hours ago
Share repurchases are a popular way to return capital to shareholders, tending to boost a stock and per-share earnings.
- Investopedia•3 hours ago
AGN shares have held up well in the last couple of days despite a weak sector.
- American City Business Journals•8 hours ago
Editas Medicine could earn upwards of $1 billion in milestone payments through a research and development alliance that it recently struck with Allergan, according to a spokeswoman for the Cambridge gene editing firm. Editas (EDIT) announced on March 14 that it would receive $90 million up front in exchange for giving Allergan (AGN) the option to license up to five preclinical programs targeting eye disease — a relatively modest sum. On Wednesday, a spokeswoman for Editas said that the company would be eligible to receive more than $200 million on each program that Allergan exercises its option to license.
AGN : Summary for Allergan plc Ordinary Shares - Yahoo Finance
Allergan plc (AGN)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||233.35 - 236.41|
|52 Week Range||184.50 - 282.59|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||6.13|
|Dividend & Yield||2.80 (1.18%)|
|1y Target Est||N/A|